Central retinal vein occlusion: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
*[[Glaucoma]] | *[[Glaucoma]] | ||
==Clinical Features== | |||
[[File:crvo.png|thumbnail|CRVO Blood and Thunder]] | [[File:crvo.png|thumbnail|CRVO Blood and Thunder]] | ||
*[[vision loss|Loss of vision]] | *[[vision loss|Loss of vision]] | ||
**Variable, ranging from vague blurring to rapid, painless monocular vision loss | **Variable, ranging from vague blurring to rapid, painless monocular vision loss | ||
Latest revision as of 20:58, 16 December 2020
Background
Risk Factors
- Diabetes mellitus
- Hypertension
- Hypercoagulable states
- Vasculitis
- Glaucoma
Clinical Features
- Loss of vision
- Variable, ranging from vague blurring to rapid, painless monocular vision loss
- Fundoscopy
- Optic disc edema, dilated and tortuous veins, diffuse retinal hemorrhages ("blood-and-thunder fundus")
Differential Diagnosis
Acute Vision Loss (Noninflamed)
- Painful
- Arteritic anterior ischemic optic neuropathy
- Optic neuritis
- Temporal arteritis†
- Painless
- Amaurosis fugax
- Central retinal artery occlusion (CRAO)†
- Central retinal vein occlusion (CRVO)†
- High altitude retinopathy
- Open-angle glaucoma
- Posterior reversible encephalopathy syndrome (PRES)
- Retinal detachment†
- Stroke†
- Vitreous hemorrhage
- Traumatic optic neuropathy (although may have pain from the trauma)
†Emergent Diagnosis
Evaluation
Management
- Consult ophtho and neuro
- No treatment regimen provides significant and consistent results
- Complex treatment possibly involving aspirin, anticoagulation, fibrinolysis, lowering IOP, topical steroids, cyclocryotherapy, photocoagulation, intravitreal injections (triamcinolone, anti-VEGF, aflibercept) while managing underlying medical diseases
- Possible benefit from LMWH plus aspirin in central retinal vein occlusion[1]
- May provide a 78% risk reduction of adverse ocular outcome in central vein occlusion
- Less benefit in branched retinal vein occlusion
Disposition
See Also
Acute Vision Loss (Noninflamed)
References
- ↑ Lazo-Langner A et al. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. 2010 Sep; 95(9): 1587–1593.